ALSO NOTED: Pfizer focuses on expanding inhaled meds R&D; Bayer's Avelox linked to liver problems;

> Pfizer is budgeting €130 million for the construction of a new facility in France to specialize in the development of inhaled meds. Report

> Bayer warned doctors that its Avelox antibiotic may lead to potentially fatal liver damage and skin disease in rare cases. Report

> Orchid Chemicals and Pharmaceuticals got FDA approval for its non-antibiotic anti-emetic drug granisetron hydrochloride. Report

> MiddleBrook Pharma has hired the investment bankers at Morgan Stanley to explore strategic alternatives, including a possible sale of company assets. Report

> A new study shows that drug-coated balloons were better at keeping leg arteries open than were conventional balloon catheters. Report

> Websites that states use to help consumers compare prescription prices often have missing, outdated, or inaccurate information, according to a report from the Center for Studying Health System Change. Report

> Vertex Pharmaceuticals plans to sell senior convertible notes and 6 million shares of common stock to raise $405 million. Report

> A new investigation by USA Today suggests that corporate policies for retail pharmacies such as Walgreens and CVS--which together fill almost one-third of all U.S. prescriptions--could promote errors by encouraging pharmacists to work at the highest possible speed. Report

> Despite spending a dramatically higher amount than before on treatments for spinal pain, Americans aren't getting great results, according to a new study. Report

> With its stock in a swoon, Nastech has cut 50 more positions. Report

And Finally... Athletes may get protection from coughs and colds by using probiotic supplements. Report

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.